European Journal of Nuclear Medicine

, Volume 24, Issue 1, pp 68–71

Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease

  • J. Booij
  • G. Tissingh
  • A. Winogrodzka
  • G. J. Boer
  • J. C. Stoof
  • E. C. Wolters
  • E. A. van Royen
Short communication

Abstract

Loss of striatal dopamine (DA) transporters in Parkinson's disease (PD) has been accurately assessed in vivo by single-photon emission tomography (SPET) studies using [123I]β-CIT. However, these studies have also shown that adequate imaging of the striatal DA transporter content can be performed only 20–30 h following the injection of [123I]β-CIT, which is not convenient for routine out-patient evaluations. Recently, a new ligand,N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)tropane (FP-CIT), became available for in vivo imaging of the DA transporter. The faster kinetics of [123I]FP-CIT have been shown to allow adequate acquisition as early as 3 h following injection. In the present study, loss of striatal DA transporters in five non-medicated PD patients was assessed on two consecutive SPET scans, one with [123I]β-CIT (24 h following injection) and one with [123I]FP-CIT (3 h following injection). The ratios of specific to non-specific [123I]FP-CIT uptake in the caudate nucleus and putamen were consistently 2.5-fold lower than those of [123I]β-CIT. However, when the uptake ratio of both ligands in these brain regions of patients was expressed as a percentage of the uptake ratio found in healthy controls, both the decrease and the variation of the data were similar. It is concluded on the basis of these findings that [123I]FP-CIT seems as good as [123I]β-CIT for the assessment of the dopaminergic deficit in PD. The faster kinetics of [123I]FP-CIT are a clear advantage.

Key words

Parkinson's disease Single-photon emission tomography Dopamine transporter imaging Cocaine analogues 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brücke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT. Binding kinetics in the human brain.J Neural Transm [Gen Sect] 1993; 94: 137–146.Google Scholar
  2. 2.
    Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease.Ann Neurol 1995; 38: 589–598.Google Scholar
  3. 3.
    Vermeulen RJ, Wolters EC, Tissingh E, et al. Evaluation of [123I]β-CIT binding with SPECT in controls, early and late Parkinson's disease.Nucl Med Biol 1995; 22: 985–991.Google Scholar
  4. 4.
    Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic and equilibrium analysis of [123I]β-CIT in vivo binding to dopamine transporters in healthy subjects.J Cereb Blood Flow Metab 1994; 14: 982–994.Google Scholar
  5. 5.
    Baldwin RM, Zea-Ponce Y, Al-Tikriti MS, et al. Regional brain uptake and pharmacokinetics of [123I]N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl)nortropane esters in baboons.Nucl Med Biol 1995; 22: 211–219.Google Scholar
  6. 6.
    Neumeyer JL, Wang S, Gao Y, et al.N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters.J Med Chem 1994; 37: 1558–1561.Google Scholar
  7. 7.
    Lundkvist C, Halldin C, Swahn C-G, et al. [O-methyl-11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolic studies, and positron emission tomography examinations.Nucl Med Biol 1995; 22: 905–913.Google Scholar
  8. 8.
    Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT.J Nucl Med 1996; 37: 1129–1133.Google Scholar
  9. 9.
    Kuikka JT, Bergström KA, Ahonen A, et al. Comparison of iodine-123 labelled 2β-carbomethocy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain.Eur J Nucl Med 1995; 22: 356–360.Google Scholar
  10. 10.
    Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT reveals marked decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; in press.Google Scholar
  11. 11.
    Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.J Neurol Neurosurg Psychiatry 1988; 51: 745–752.Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • J. Booij
    • 1
  • G. Tissingh
    • 2
  • A. Winogrodzka
    • 2
  • G. J. Boer
    • 3
  • J. C. Stoof
    • 2
  • E. C. Wolters
    • 2
  • E. A. van Royen
    • 1
  1. 1.Department of Nuclear Medicine, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  2. 2.Department of Neurology, Research Institute NeurosciencesVrije UniversiteitThe Netherlands
  3. 3.Netherlands Institute for Brain ResearchThe Netherlands

Personalised recommendations